[Click e-Stock] "Neurophet Set to Accelerate at Year-End... Brain Disease AI Solutions to Revolutionize Healthcare"

On July 1, Korea Investment & Securities predicted that Neurophet would begin to accelerate its growth in earnest starting at the end of this year.

Neurophet, established in 2016, is a company specializing in artificial intelligence (AI) solutions for brain diseases. It develops diagnostic tools, treatment planning, and medical device solutions for brain disorders by utilizing brain imaging analysis technology. Based on its proprietary analysis engine, Neurophet rapidly and accurately analyzes brain imaging data such as MRI (magnetic resonance imaging) and PET (positron emission tomography) to support clinical decision-making for medical professionals.

The company's main products include 'Neurophet AQUA,' a diagnostic support software for degenerative brain diseases (MRI-based); 'Neurophet SCALE PET,' a PET image quantitative analysis software; and 'Neurophet AQUA AD,' a comprehensive imaging biomarker solution for Alzheimer's disease. This year's estimated revenue breakdown is AQUA 36.6%, SCALE PET 31.5%, CRO 14.0%, and others 18.0%.

Yoon Chulhwan, a researcher at Korea Investment & Securities, explained, "Alzheimer's disease is a representative degenerative brain disorder, characterized by symptoms such as memory decline, cognitive impairment, and behavioral changes. As the disease progresses, the ability to perform daily activities deteriorates." He added, "The main cause of onset known so far is the abnormal accumulation of amyloid-beta (Aβ) protein in the brain, which forms plaques and leads to the damage and death of nerve cells."

Both MRI and PET imaging technologies are used in the diagnosis of Alzheimer's disease. MRI is used to check the anatomical structure of the brain and the degree of atrophy to differentiate types of dementia, while PET scans visualize the distribution and accumulation of amyloid-beta protein in the brain, contributing to a definitive diagnosis of Alzheimer's disease. However, subtle atrophy on MRI can be missed even by experienced radiology experts, and the number of nuclear medicine specialists capable of interpreting PET images is extremely limited both domestically and internationally.

Regarding this, Yoon stated, "These limitations of conventional imaging diagnostics can be addressed through AI solutions for brain diseases," and expressed expectations that "Neurophet's AI technology will be the key to reducing interpretation variability in clinical settings and improving diagnostic accuracy." He added, "Based on these strengths, Neurophet plans to further expand its competitiveness in the global market."